Not all long-established ADC Biotechs can achieve a successful exit like Seagen (Seattle Genetics). Today, Mersana Therapeutics, a 23-year-old veteran biotech, has reached its most desperate moment. With a cumulative deficit of $900 million and only $134.6 million left in cash, its two core pipeline products are still in Phase I clinical trials. To sustain … Read more
Click the “blue text” to follow us Every year, millions of patients worldwide are waiting for organ transplants, but there is a severe shortage of donated organs. Statistics show that in the United States alone, about 20 people die each day waiting for a suitable organ. Faced with this dilemma, scientists have proposed a bold … Read more
In the pharmaceutical industry, there is a “double ten law”: the average cost of developing an innovative drug from initiation to market exceeds $1 billion, takes more than 10 years, and about 90% of drugs fail during clinical trials. Hong Kong-listed JingTai Technology is reshaping the productivity paradigm of drug development through technological transformation: the … Read more
Expert Forum Authors: Xue Jiaohao1, Li Zhipeng1, Zhao Yuanli2 Affiliations: 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 2Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Corresponding Author: Zhao Yuanli Funding Project: Central High-Level Hospital Clinical Research Special Project (2023-PUMCH-E-011) Source: Chinese Journal of Medicine, 2025, 16(2): 277-284. Cerebrovascular … Read more
Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more
Follow Xiaobai Learning Medicine As of now, 17 ADC drugs have been approved worldwide, of which 5 ADCs are coupled with lysine. Table 1 Summary of ADC Drugs Coupled with Lysine Approved Product Name Company Target DAR Toxin Linker Antibody Type Payload Type Mylotarg Pfizer CD33 2~3 Calicheamicin Hydrazone Link (Acid-labile) IG4 DNA Damaging Agent … Read more
The AACR is always bustling every year, and this year I am particularly focused on the progress of dual payload ADCs. I have written several articles on this topic before, and just a few days ago, I was discussing with my supervisor that “I haven’t seen any dual payload ADCs advancing to clinical trials yet,” … Read more
If a few years ago, presenting a simple PowerPoint on the ADC field could impress without the need for future visions, cutting-edge technologies, or a vibrant pipeline forest, today, the ADC field requires substantial content to make an impact. This shift is attributed to advancements in industry technology and rising awareness. Data shows that from … Read more
After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more